Equine Herpesvirus (EHV-1, EHV-4)

Equine herpesvirus vaccine provides protection against diseases caused by equine herpesvirus type 1 and type 4, which are among the most common viral pathogens affecting horses worldwide. These vaccines are classified as risk-based by the American Association of Equine Practitioners, meaning they are recommended for horses with specific risk factors rather than for all horses universally. EHV-1 and EHV-4 can cause respiratory disease, abortion in pregnant mares, neonatal foal death, and in the case of certain EHV-1 strains, severe neurological disease known as equine herpesvirus myeloencephalopathy. Vaccination represents an important component of prevention strategies for these significant equine diseases.

Equine herpesvirus type 4 is the primary cause of equine viral rhinopneumonitis, a respiratory disease characterized by fever, nasal discharge, cough, and depression. While most adult horses recover from respiratory infection without complications, the disease can spread rapidly through groups of horses and cause significant economic impact due to time out of training and competition. Equine herpesvirus type 1 can also cause respiratory disease, but it is additionally responsible for abortion storms on breeding farms and the devastating neurological form of disease that has caused significant outbreaks in recent years.

Several vaccine formulations are available for equine herpesvirus prevention, including killed virus vaccines and modified live virus vaccines. Killed vaccines are safe for use in pregnant mares and are the standard choice for abortion prevention protocols. Modified live vaccines may stimulate stronger cellular immunity and are sometimes preferred for respiratory disease prevention in non-pregnant horses. Some combination products include both EHV-1 and EHV-4 antigens along with other respiratory pathogens such as equine influenza virus. The veterinarian will recommend the most appropriate product based on the horse's individual risk factors and vaccination goals.

It is important to understand that current equine herpesvirus vaccines have limitations. While they effectively reduce the severity of respiratory disease and significantly decrease abortion rates in vaccinated mares, they do not prevent infection or eliminate viral shedding completely. Additionally, protection against the neurological form of EHV-1 disease has not been demonstrated with currently available vaccines. Despite these limitations, vaccination remains a valuable tool in herpesvirus control programs, particularly when combined with good biosecurity practices. Horses at high risk should receive regular vaccination according to veterinary recommendations.

The primary indications for equine herpesvirus vaccination include prevention of respiratory disease caused by EHV-1 and EHV-4, reduction of abortion risk in pregnant mares, and protection of neonatal foals through maternal immunity. Vaccination is particularly recommended for horses with increased exposure risk, including those at boarding facilities, training centers, and competition venues where mixing of horses from different sources is common. Performance horses that travel frequently encounter numerous potential sources of infection and benefit from regular vaccination.

Prevention of equine viral rhinopneumonitis is an important indication for herpesvirus vaccination, particularly in young horses and those in high-density environments. Respiratory outbreaks can spread rapidly through barns and training facilities, affecting multiple horses and disrupting training schedules. While vaccinated horses may still become infected, they typically experience milder disease and shed virus for shorter periods, helping to limit outbreak severity. Regular vaccination of all horses at a facility contributes to overall herd immunity and outbreak prevention.

Abortion prevention in pregnant mares represents a critical application of equine herpesvirus vaccination on breeding farms. EHV-1 abortion typically occurs during the last trimester of pregnancy and can affect multiple mares during outbreak situations, causing devastating economic and emotional losses. Killed virus vaccines administered according to specific protocols during pregnancy have been shown to significantly reduce abortion rates. Most protocols recommend vaccination at the fifth, seventh, and ninth months of pregnancy, though specific recommendations may vary based on farm history and veterinary guidance.

Protection of neonatal foals through maternal antibody transfer is another important benefit of mare vaccination. Foals born to vaccinated mares receive passive immunity through colostrum that provides some protection during the early months of life when their own immune systems are still developing. This is particularly important because young foals are susceptible to severe respiratory disease and can serve as a source of infection for pregnant mares on the same farm.

Horses at facilities with frequent new arrivals, such as sales preparation barns, show barns, and lesson programs, are at increased risk for herpesvirus exposure and may benefit from more frequent vaccination. The veterinarian will assess the specific risk factors present at each facility and recommend appropriate vaccination frequencies, which may range from every three to six months for high-risk horses to annual vaccination for lower-risk individuals.

Equine herpesvirus vaccination protocols vary depending on the specific product used, the horse's age and risk factors, and whether the primary goal is respiratory disease prevention or abortion prevention. All vaccination decisions should be made in consultation with a veterinarian who can evaluate the individual horse's circumstances and recommend the most appropriate approach. Proper vaccine selection, timing, and administration are essential for achieving optimal protection against these important equine pathogens.

For initial vaccination of previously unvaccinated horses, most protocols recommend a primary series of two or three doses administered three to four weeks apart. This initial series establishes baseline immunity that is then maintained through periodic boosters. The timing of the primary series should be planned so that protection is in place before anticipated exposure periods, such as the competition season for performance horses or breeding season for mares. Young horses typically begin their vaccination series after maternal antibodies have waned, usually between four and six months of age.

Booster frequency for equine herpesvirus vaccines depends on the level of risk and the specific disease manifestation being targeted. For respiratory disease prevention in high-risk horses, boosters every three to six months may be recommended, particularly for horses that travel frequently or are housed at facilities with high turnover. For lower-risk horses with limited exposure to outside animals, annual or semi-annual boosters may be sufficient. The veterinarian will help determine the appropriate booster schedule based on individual circumstances.

Pregnant mare vaccination protocols for abortion prevention require specific timing to maximize protection during the vulnerable late gestational period. The standard recommendation is vaccination at five, seven, and nine months of pregnancy using killed virus vaccines. Some veterinarians recommend an additional dose at three months of pregnancy for mares on farms with a history of EHV abortion. Only killed virus vaccines should be used in pregnant mares, as modified live vaccines are not approved for use during pregnancy. Strict adherence to the vaccination schedule is essential for optimal protection.

The vaccine is administered by intramuscular injection, typically in the neck muscles or hindquarter. Proper aseptic technique should be employed, and the injection site should be noted in the medical record. Following vaccination, horses may experience mild local reactions that typically resolve within a few days. Horses should have reduced workloads for a day or two following vaccination to allow for optimal immune response development.

Missed doses or delayed boosters should be addressed promptly to restore protection. Horses that are only slightly overdue may receive a single booster, while those significantly overdue may need to restart with a two-dose series. For pregnant mares, any deviation from the recommended vaccination schedule should be discussed with the veterinarian immediately, as timing is critical for abortion prevention.

Equine herpesvirus vaccines have a good safety record when administered according to manufacturer guidelines and veterinary recommendations. The majority of vaccinated horses experience no significant adverse effects. Both killed virus and modified live virus formulations are generally well-tolerated, though the type and frequency of reactions may differ somewhat between product types. Understanding potential side effects allows horse owners to monitor their animals appropriately and recognize when veterinary attention may be needed.

Local reactions at the injection site are the most commonly observed side effects following herpesvirus vaccination. Horses may develop swelling, firmness, warmth, or tenderness in the muscle where the vaccine was administered. These reactions typically appear within 24 to 48 hours and resolve within several days without specific treatment. Killed virus vaccines, which contain adjuvants to enhance immune response, may cause more pronounced local reactions than modified live products. Cold compresses during the first day followed by warm compresses may help reduce discomfort if local reactions occur.

Mild systemic reactions including low-grade fever, decreased appetite, and lethargy may occur in some horses following vaccination. These signs usually appear within 24 to 48 hours after vaccination and resolve within one to two days. Such reactions reflect normal immune system activation and generally do not require treatment beyond supportive care including rest and access to water and feed. Horses experiencing systemic reactions should have reduced activity and should not be transported or competed until they have fully recovered. If signs persist beyond 48 hours or worsen, veterinary evaluation is indicated.

More significant adverse reactions are uncommon but possible with any vaccine. Allergic reactions ranging from hives and facial swelling to anaphylaxis may occur, typically within minutes to hours of vaccination. Veterinarians are prepared to manage acute allergic reactions and may pre-treat horses with a history of vaccine sensitivity. Any horse experiencing a severe reaction should have this documented in their medical record for future reference. Subsequent vaccination decisions should be made carefully in consultation with the veterinarian.

Rare complications such as injection site abscesses, prolonged swelling, or unusual systemic reactions should be reported to both the veterinarian and vaccine manufacturer. While modified live vaccines are generally not recommended during pregnancy, inadvertent administration has occurred without documented adverse effects in most cases. However, pregnant mares should receive only killed virus vaccines as specified by manufacturer labels and veterinary guidelines.

Equine herpesvirus vaccination with modified live virus products is contraindicated in pregnant mares. While these vaccines are safe and effective for respiratory disease prevention in non-pregnant horses, the theoretical risk of vaccine virus causing abortion or fetal harm precludes their use during pregnancy. Only killed virus vaccines should be administered to pregnant mares, and product labels should be carefully reviewed to confirm pregnancy safety. If a mare's pregnancy status is uncertain, a killed virus vaccine should be selected.

Horses with known hypersensitivity to equine herpesvirus vaccines or their components should not be vaccinated with products that have previously caused reactions. Severe allergic reactions including anaphylaxis preclude future use of the same vaccine product. In such cases, alternative formulations from different manufacturers may be considered, though cross-reactivity is possible. Any history of vaccine reactions should be clearly documented in the horse's medical record and communicated to all veterinary personnel.

Acutely ill horses with fever or systemic disease should not be vaccinated until they have recovered. Vaccination during illness may result in suboptimal immune responses and could complicate diagnosis and treatment of the underlying condition. Additionally, the stress of illness may increase the risk of adverse vaccine reactions. Once the horse has recovered and been cleared by the veterinarian, vaccination can proceed according to the recommended schedule.

Severely immunocompromised horses may not mount adequate immune responses to vaccination and require careful evaluation. While killed virus vaccines are generally safe for immunocompromised animals, the expected protection may not develop fully. Horses with conditions affecting immune function or those receiving immunosuppressive medications should be assessed individually by their veterinarian. In some cases, modifications to vaccination protocols or acceptance of reduced efficacy may be necessary.

Equine herpesvirus vaccines may interact with other vaccines and medications, and these potential interactions should be considered when planning vaccination schedules. While simultaneous administration of multiple vaccines is common practice in equine medicine for convenience, excessive antigenic stimulation could theoretically reduce immune responses to individual products or increase the risk of adverse reactions. Veterinarians typically follow professional guidelines regarding the number and combination of vaccines that can be safely administered at one time.

Corticosteroids and other immunosuppressive medications may reduce the effectiveness of herpesvirus vaccination by suppressing immune responses. Horses receiving systemic corticosteroids for inflammatory conditions, allergies, or immune-mediated diseases may not develop adequate protective antibody levels following vaccination. When possible, vaccination should be scheduled to avoid periods of immunosuppressive therapy. If vaccination cannot be delayed, additional booster doses may be recommended after treatment ends.

Combination vaccines that include equine herpesvirus antigens along with other respiratory pathogens such as influenza virus are widely used and well-studied. These products are formulated to provide effective immunity against all included diseases when administered according to label directions. The convenience of combination products makes them attractive for routine vaccination programs, though some horses may require separate products based on individual needs, competition requirements, or reaction history.

Antibiotics do not interfere with killed or modified live herpesvirus vaccines, as these products do not rely on bacterial replication for efficacy. Horses receiving antibiotic therapy for infections can generally proceed with scheduled herpesvirus vaccination without concerns about reduced effectiveness. However, the underlying condition requiring antibiotics may warrant delaying vaccination until the horse has recovered. Non-steroidal anti-inflammatory drugs are not known to significantly impair vaccine responses, though some veterinarians prefer to avoid their use immediately around vaccination time unless medically necessary.

All equine herpesvirus vaccination decisions should be made in consultation with a veterinarian who can evaluate the horse's individual risk factors, health status, and vaccination history. Proper vaccine selection is critical, particularly for pregnant mares where only killed virus products should be used. The veterinarian will recommend the most appropriate product and schedule based on the horse's specific circumstances and the primary goals of vaccination.

Horses should be observed following vaccination for signs of adverse reactions. While severe reactions are uncommon, they require immediate veterinary attention. Vaccination appointments should be scheduled to allow for monitoring and should not immediately precede transport, competition, or other stressful activities. For pregnant mares, close adherence to the recommended vaccination schedule is essential for optimal abortion prevention.

It is important to understand the limitations of current equine herpesvirus vaccines. These vaccines reduce disease severity and help prevent abortion, but they do not prevent infection or eliminate viral shedding completely. Vaccinated horses can still become infected and can transmit virus to other horses. Current vaccines have not been shown to provide protection against the neurological form of EHV-1 disease. Vaccination should be considered one component of a comprehensive herpesvirus prevention program that includes biosecurity measures.

Biosecurity practices are essential complements to vaccination for herpesvirus control. New horses should be isolated for three to four weeks before introduction to the resident population. Horses returning from competitions or other off-farm events should also be isolated. Temperature monitoring of isolated horses helps detect infection early. During outbreaks, strict biosecurity measures including movement restrictions, dedicated equipment, and enhanced hygiene are critical for disease control regardless of vaccination status.

Vaccination records should be maintained accurately and be readily available for review. Competition organizations may require documentation of herpesvirus vaccination for entry, and some facilities require proof of vaccination for boarding. The vaccination record should include dates, products used, lot numbers, and any adverse reactions observed. For pregnant mares, records should clearly document adherence to the abortion prevention vaccination schedule.

Equine herpesvirus vaccines require proper storage to maintain potency and effectiveness. Both killed virus and modified live virus products must be refrigerated at temperatures between 35 and 46 degrees Fahrenheit. Exposure to temperatures outside this range can compromise vaccine efficacy. Freezing can damage vaccine components and render products ineffective, while excessive heat accelerates degradation. Veterinary practices maintain dedicated vaccine refrigerators with temperature monitoring to ensure proper storage conditions.

Modified live virus vaccines may have additional handling requirements due to the presence of live, attenuated organisms. These products may need to be reconstituted before use and should be administered promptly after preparation. Reconstituted modified live vaccines have limited stability and should not be stored for later use. Any unused reconstituted vaccine should be disposed of properly according to manufacturer guidelines and local regulations for biological waste.

During farm calls, veterinarians transport vaccines in insulated coolers with ice packs to maintain cold chain integrity. Vaccines should not be left in vehicles where temperature fluctuations can be extreme or exposed to direct sunlight during the vaccination process. Once removed from the cooler, vaccines should be used promptly. Horse owners should rely on their veterinarian to obtain and store vaccines properly rather than purchasing vaccines for storage at the barn.

Equine herpesvirus affects horses of all breeds, and vaccination recommendations are based primarily on risk factors rather than breed characteristics. Draft horses, warmbloods, light horses, ponies, and miniature horses are all susceptible to herpesvirus infection and may benefit from vaccination depending on their individual circumstances. The decision to vaccinate is guided by factors such as exposure risk, reproductive status, and management rather than breed type.

Breeding animals of all breeds warrant particular attention regarding herpesvirus vaccination. Pregnant mares on breeding farms represent a primary population for abortion prevention vaccination protocols. Stallions used for breeding may also benefit from regular vaccination to reduce viral shedding and limit transmission risk to mares. Breeding farms should implement comprehensive herpesvirus vaccination programs for all resident horses to minimize outbreak risk.

Performance horses of various breeds that travel for competition have increased exposure risk and typically benefit from more frequent herpesvirus vaccination. Horses competing in disciplines with extensive travel schedules, such as show jumping, eventing, dressage, and breed shows, encounter horses from many different origins. Competition venues where horses are stabled in close proximity facilitate disease transmission. Vaccination every three to six months may be recommended for heavily campaigned horses.

Breed-specific genetic conditions do not directly affect herpesvirus vaccine safety or efficacy. Arabian horses with severe combined immunodeficiency should not receive modified live virus vaccines, but killed products may be used with veterinary guidance. Horses with other underlying health conditions that affect immune function should be evaluated individually. For the vast majority of horses regardless of breed, herpesvirus vaccination is safe and effective when used according to veterinary recommendations.

Equine herpesvirus vaccine is classified as a risk-based vaccine and is often administered alongside equine influenza vaccine, another risk-based respiratory vaccine. Many combination products include both herpesvirus and influenza antigens, providing convenient protection against the major viral causes of equine respiratory disease. Horses at high risk for respiratory disease exposure typically receive regular vaccination against both pathogens according to schedules determined by their veterinarian.

Other risk-based vaccines that may be recommended based on individual circumstances include those for strangles, Potomac horse fever, botulism, and anthrax. The veterinarian evaluates each horse's risk factors to determine which vaccines are appropriate. Core vaccines recommended for all horses include those for Eastern and Western Equine Encephalomyelitis, tetanus, rabies, and West Nile Virus. Comprehensive vaccination programs include both core and appropriate risk-based vaccines.

No specific antiviral treatments are approved for equine herpesvirus infections, making prevention through vaccination and biosecurity essential. Supportive care is the mainstay of treatment for horses with respiratory or neurological herpesvirus disease. Anti-inflammatory medications may help manage fever and discomfort during respiratory infections. Neurological cases may require intensive supportive care including sling support for recumbent horses, fluid therapy, and anti-inflammatory treatment. The high morbidity associated with severe herpesvirus disease and the lack of specific treatment options underscore the importance of prevention through vaccination and biosecurity measures for horses at risk.